New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing ReferenceAstagraf XL (tacrolimus extended-release capsules; Astellas) has been approved for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycop…
MedPage TodayLong-Release Tacrolimus Wins FDA NodMedPage TodaySpecific indications for the extended-release form are for prophylaxis of graft rejection in kidney transplant patients also receiving mycophenolate mofetil and corticosteroids, with or with…
MedPage TodayU.S. Launch of Astellas Astagraf XLZacks.com… received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil…
Astellas Announces FDA Approval of ASTAGRAF XLTM (tacrolimus extended …PipelineReview.com (press release)… Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients rec…
|
Astellas: FDA OKs Kidney Transplant Rejection Drug
Genetic Engineering News … announced it has received FDA approval for Astragraf XL™ (tacrolimus extended-release capsules) for the prophylaxis of kidney rejection in patients receiving a transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab … |
Lymphoma immunotherapy to train the body to fight bad B-cells like viruses …MedCity NewsCurrently approved biologics for lymphoma include Rituximab (Genentech), Ibritumomab tuixetan (Spectrum Pharmaceuticals) and Tositumomab (GSK), which are part of …
Maternal Antibodies and Autism and Flu Shots Oh Why?Age of AutismIn a study published in Translational Psychiatry, researchers report that 23% of all cases of autism may result from the presence of maternal antibodies that interfere with fetal brain de…
|
FDA approves Astellas once-daily organ rejection drug
PharmaTimes The thumbs-up is for the once-daily oral drug to be used with a regimen that includes treatment with with mycophenolate mofetil and corticosteroids, with or without basiliximab induction. Sef Kurstjens, chief medical officer at Astellas’ US unit, said … Astellas reports FDA approval of anti-rejection drugNephrologyNews.com Astellas Pharma secures US FDA approval for ASTAGRAF XLPharmaceutical Business Review |
|
FDA backs Astellas’ Astragraf XL for kidney transplant rejection prophylaxis
The Pharma Letter … Astellas Pharma’s (TYO: 4503) Astragraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab … |
VIDEO: Dr. De Meirleir on Oxygen Therapy, Rituximab, Ampligen, Pacing, Fecal …ProHealthAdministration of oxygen therapy has advantages and disadvantages. Oxygen increases the release of free radicals, which can be harmful. On the other hand oxygen ca…